Check for updates

OPEN ACCESS

EDITED BY Jianzhen Xu, Shantou University, China

REVIEWED BY

Meng Zhou, Wenzhou Medical University, China Dangdang Li, Northeast Forestry University, China Qi-En Yang, Northwest Institute of Plateau Biology (CAS), China

*CORRESPONDENCE

Pengling Ge, penglingge@126.com, penglingge@yeah.net Junzhi Wang, drvolodia@163.com

SPECIALTY SECTION

This article was submitted to Computational Genomics, a section of the journal Frontiers in Genetics

RECEIVED 02 September 2022 ACCEPTED 21 October 2022 PUBLISHED 03 November 2022

CITATION

Zhang Y, Han D, Yu X, Shao X, Zong C, Zhang M, Wang J, Liang J and Ge P (2022), MiRNA-190a-5p promotes primordial follicle hyperactivation by targeting PHLPP1 in premature ovarian failure. *Front. Genet.* 13:1034832. doi: 10.3389/fgene.2022.1034832

COPYRIGHT

© 2022 Zhang, Han, Yu, Shao, Zong, Zhang, Wang, Liang and Ge. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

MiRNA-190a-5p promotes primordial follicle hyperactivation by targeting PHLPP1 in premature ovarian failure

Yuchi Zhang^{1,2}, Dongwei Han¹, Xiaoyan Yu¹, Xinyu Shao^{1,3}, Chuju Zong^{1,4}, Manyu Zhang¹, Junzhi Wang⁵*, Jingwen Liang¹ and Pengling Ge¹*

¹Department of Pharmacology, School of Basic Medical Sciences, Heilongjiang University of Chinese Medicine, Harbin, China, ²Department of Neurology, Faculty of Medicine, Shimane University, Izumo, Japan, ³The First Affiliated Hospital of Qiqihar Medical University, Qiqihar, China, ⁴Heilongjiang Institute for Drug Control, Harbin, China, ⁵Department of Dermatology, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China

We previously screened 6 differentially expressed miRNAs in ovarian tissues of 4-vinylcyclohexene diepoxide (VCD)-treated premature ovarian failure (POF) model in SD rats, including miRNA-190a-5p, miRNA-98-5p, miRNA-29a-3p, miRNA-144-5p, miRNA-27b-3p, miRNA-151-5p. In this study, to investigate the mechanisms causing the onset of POF, we first identified miRNAs with earlier differential expression at consecutive time points in the VCD-treated rat POF model and explored the mechanisms by which the target miRNAs promote POF. The SD rats were injected with VCD for 15 days to induce POF. Additionally, we collected rat blood and ovaries at the same time every day for 15 consecutive days, and luteinizing hormone (LH), follicle-stimulating hormone (FSH), Anti-Mullerian hormone (AMH), and estradiol (E₂) serum levels were detected by ELISA. Six miRNAs expression were measured in rat ovaries by gRT-PCR. Dual-luciferase reporter gene assays were employed to predict and verify the target gene (PHLPP1) of target miRNAs (miRNA-190a-5p). Western blot was examined to detect the expression levels of PHLPP1, AKT, p-AKT, FOXO3a, p-FOXO3a, and LHR proteins on the target gene PHLPP1 and its participation in the primordial follicular hyperactivation-related pathways (AKT-FOXO3a and AKT-LH/LHR). During the VCD modeling POF rat ovaries, miRNA-190a-5p was the first to show significant differential expression, i.e., 6th of VCD treating, and PHLPP1 was verified to be a direct downstream target of it. Starting from the 6th of VCD treatment, the more significant the up-regulation trend of miRNA-190a-5p expression, the more obvious the down-regulation trend of PHLPP1 and LHR mRNA and protein expression, accompanied by the more severe phosphorylation of AKT and FOXO3a proteins, thus continuously over-activating the rat primordial follicle to promote the development of POF. In conclusion, miRNA-190a-5p may become a potential biomarker for early screening of POF, and it can continuously activate primordial follicles in rats by targeting the expression of PHLPP1 and key proteins in the AKT-FOXO3a and AKT-LH/LHR pathways.

KEYWORDS

premature ovarian failure (POF), 4-vinylcyclohexene diepoxide (VCD), miRNA-190a-5p, PHLPP1, AKT, LHR, FOXO3a

1 Introduction

With the change in people's lifestyles and fertility concepts, women's childbearing age is moving backward, and the incidence of infertility is increasing year by year (Harumi, 2009). According to the World Health Organization (WTO) reported, infertility will become the third largest disease after cancer and cardiovascular disease (Vayena et al., 2002; Dong et al., 2021). Meanwhile, the latest survey showed that the incidence rate of infertility in the world is 15% to 20%, and the number of patients ranges from 48 million to 180 million (Thoma et al., 2021). Among them, premature ovarian failure (POF) is one of the important pathogenic factors that cause infertility in women of childbearing age, and it is a gynecological disease with unclear etiology (Shelling, 2010). Most patients are found to be in a state of POF due to menstrual disorders, amenorrhea, and infertility (Shelling, 2010). However, at present, the onset time of POF cannot be determined, and it has the characteristics of being irreversible or difficult to reverse (Santoro, 2003). Thus, early detection in the initial process of POF is an urgent medical research problem.

With the deepening of medical research, more and more evidence has confirmed that the over-activation of primordial follicles is an important pathological mechanism for POF, and it is also caused by the premature depletion of ovarian reserves (Adhikari et al., 2013; Zhou et al., 2017; Chakravarthi et al., 2020; Maidarti et al., 2020). Therefore, it is particularly important to find out the regulatory factors of the over-activation of primordial follicles to explore the mechanism of POF. Studies have shown that a common ovarian toxic chemical, 4vinylcyclohexene diepoxide (VCD), accelerates ovarian failure by specifically activating primordial follicles (Hu et al., 2006; Fernandez et al., 2008; Kappeler and Hoyer, 2012; Lee et al., 2017). In our previous research, we replicated the POF rat model by VCD (Li et al., 2014), and detected 6 differentially expressed miRNAs between POF rats and normal rats by rat genome-wide miRNA expression profile technology, including miRNA-190a-5p, miRNA-98-5p, miRNA-29a-3p, miRNA-144-5p, miRNA-27b-3p, miRNA-151-5p (Kuang et al., 2014). Then, we speculated that the 6 differentially expressed miRNAs might be involved in the occurrence of POF. However, it is unknown whether these differentially expressed miRNAs are the cause of excessive activation of primordial follicles in early premature ovarian failure or the result of hyperactivation of primordial follicles. Thus, this study will detect the expression of 6 miRNAs at a continuous time point from the first day of the application of VCD to replicate the POF rat model, identify the target miRNAs with early differential expression, and verify whether they can induce POF.

2 Materials and methods

2.1 Animals

Twelve weeks old female Sprague-Dawley (SD) rats, weighing 200 \pm 20 g, were supplied by the Liaoning Changsheng Biotechnology Co., Ltd. (Benxi, China) and were housed in the Heilongjiang University of Chinese Medicine with SPF conditions. The rats were housed in a temperature (20 \pm 1°C)-and humidity (50 \pm 5%)-controlled animal facility and maintained on a 12-h light/ dark cycle and were acclimatized for 1 week before the experiment and allowed free access to a rodent diet and tap water. All experiments were approved by the Animal Experimental Ethical Committee of Heilongjiang University of Chinese Medicine (Heilongjiang, China) and performed by the Guide for the Care and Use of Laboratory Animals.

2.2 Experimental design

Two hundred female SD rats with an estrous cycle of 5 days were selected as experimental animals, we randomly divided them into two groups: The control groups (n = 100)



FIGURE 1

The experimental design of this study. The SD female rats divided into two groups: The VCD-treated group and Control group. The two group rats were sacrificed at the same time every day (D1-D15) for 15 consecutive days. After estrous cycle testing, the POF model rats also were collected. Each rat was detected with serum hormone levels (E_2 , LH, FSH, and AMH) and screened for early differential expression of target miRNAs from those significantly differentially expressed on POF model rats (miRNA-190a-5p, miRNA-98-5p, miRNA-29a-3p, miRNA-144-5p, miRNA-27b-3p, and miRNA-151-5p). Subsequently, ovarian tissues from rats on the 6th (D6), 10th (D10), 15th (D15), and 45th (D45) of VCD injection were selected to detect the expression levels of target genes of target miRNAs and mRNAs and proteins on the primordial follicle hyperactivation signaling pathway.

TABLE 1 gRT-PCR primers of miRNAs.

Gene	Forward primer sequence $[5' \rightarrow 3']$	Stem-loop primer sequence $[5' \rightarrow 3']$	Accession ID	Primer melting temperature (T _m , °C)
rno-miRNA- 190a-5p	CGCGCGTGATATGTTTGA TATA	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTG GATACGACACCTAA	NR_031906	77.5
rno-miRNA- 144-5p	GCGCGGGATATCATCATA TACT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTG GATACGACACTTAC	NR_031890	78
rno-miRNA- 27b-3p	CGGGTTCACAGTGGCTAA	CCTGTTGTCTCCAGCCACAAAAGAGCACAATATTTC AGGAGACAACAGGGCAGAAC	NR_031832	78
rno-miRNA- 29a-3p	CGGGTAGCACCATCTGAAA	CCTGTTGTCTCCAGCCACAAAAGAGCACAATATTTC AGGAGACAACAGGTAACCGA	NR_031836	77.2
rno-miRNA- 98-5p	CGGGGTGAGGTAGTAAGTTG	CCTGTTGTCTCCAGCCACAAAAGAGCACAATATTTC AGGAGACAACAGGAACAATA	NR_031855	76
rno-miRNA- 151-5p	CGGTCGAGGAGCTCACA	CCTGTTGTCTCCAGCCACAAAAGAGCACAATATTTC AGGAGACAACAGGACTAGAC	NR_031798	78
U6	CCTGCTTCGGCAGCACA			80.3

Note: Universal reverse primer in rno-miRNA-27b-3p, rno-miRNA-29a-3p, rno-miRNA-98-5p and rno-miRNA-151-5p was: CAGCCACAAAAGAGCACAAT., The other universal reverse primer in rno-miRNA-190a-5p and rno-miRNA-144-5p was: AGTGCAGGGGTCCGAGGGTATT, The universal reverse primer of U6 was AACGCTTCACGAATTTGCGT.

TABLE 2 qRT-PCR primers of mRNAs.

Gene	Forward primer sequence $[5' \rightarrow 3']$	Reverse primer sequence [5'→3']	Accession ID	Primer melting temperature (T _m , °C)	Product length
Phlpp1	AGACGCCAGGTCATTCTGTG	TTGACGCAGCCATCGTAAGT	NM_021657.1	60	216 bp
Akt1	CAAGATGTGTATGAGAAGAAG CTGA	GTTCACTGTCCACAC ACTCCA	NM_033230.2	60	154 bp
Foxo3a	GTCACGACAAGTTCCCCAGT	AGTTTGAGGGTCTGC TTTGCC	NM_001106395.1	60	261 bp
Lhr	TCGCCCTGTCTTCCTACTCA	TGGCGGAATAAAGCGTCTCG	NM_012978.1	60	213 bp
Gapdh	AGTGCCAGCCTCGTCTCATA	GATGGTGATGGGTTTCCCGT	NM_017008.3	60	248 bp

and the VCD-treated groups (n = 100). Then the rats were intraperitoneally injected with sesame oil or sesame oil plus VCD (80 mg/kg/day) for 15 consecutive days according to our previous study (Kuang et al., 2014). At the same time, we sacrificed the rats in the control group and VCD-treated group every day (D1-D15, n = 6) for 15 consecutive days, and collected the blood and ovaries. Then we used the vaginal cytology method to observe the changes in the estrous cycle of rats. After 30 consecutive days of observation, the rats with estrous cycle disorder were taken as the POF model group rats. After 30 days of estrous cycle testing, we also collected the blood and ovaries of the D45 control group (n = 6) and the VCD-treated group (n = 6) rats. At the end of the experimental period, all rats were sacrificed by CO2 inhalation. All blood samples were centrifuged at 4,000 r/ min and 4°C for 20 min to obtain blood serum samples for Enzyme-Linked Immunosorbent (ELISA) assays. After blood serum collection, all the ovaries were collected. From each rat, one ovary was rapidly frozen by liquid nitrogen and stored at 80°C for Quantitative real-time PCR (qRT-PCR), and the

other ovary was stored at -80° C for Western blot analysis (Figure 1).

2.3 Enzyme-Linked Immunosorbent assays (ELISA)

The levels of rat serum estradiol (E_2), anti-Mullerian hormone (AMH), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) were determined by ELISA kits (Cloud-Clone Corp Inc. United States) following the manufacturer's instructions. Briefly, LH, AMH, E_2 or FSH standards at a final concentration of 8000, 2666.67, 888.89, 296.30, 98.77, and 0 pg/ml, 10000, 333.33, 1111.1, 370.4, 123.5, and 0 pg/ml, 1000, 333.33, 111.11, 37.04, 123.5, and 0 pg/ml or 600, 200, 66.67, 22.22, 7.41, 2.4, and 0 ng/ml or diluted rat serum were added to anti-LH, AMH, E_2 or FSH antibody-coated wells and incubated for 30 min. After washing five times, the horseradish peroxide (HRP)-conjugated detection antibodies were added, followed by the addition of the substrate solution. The optical density (OD) value was determined at a wavelength of 450 nm.



2.4 RNA extraction and quantitative realtime PCR (qRT-PCR)

According to the manufacturer's instructions, total RNA was extracted from whole ovaries by TRIzol reagent (Invitrogen, United States) and miRNA or mRNA easy Minikit (Qiagen, Valencia, CA, United States). In addition, RNA concentrations were determined by NanoDrop ND-1000 spectrophotometer (Wilmington, DE, United States).

For qRT-PCR experiments, the RNA was reverse-transcribed into cDNA with a RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher, United States) following the manufacturer's instructions. Quantitative PCR reaction was run on a CFX Connect Real-Time PCR Detection Instrument (BioRad, United States). Expression of the selected miRNAs was quantified by qRT-PCR, after reverse transcription with miRNA-specific stem-loop primers. The primer sequences are shown in Tables 1, 2 to amplify fragments. The data were normalized to expression levels of the housekeeping genes U6 and GAPDH, respectively, and the $2^{-\Delta\Delta CT}$ method was used to calculate relative expression levels.

2.5 Dual-luciferase reporter gene assay

Dual-Luciferase Reporter Gene Assay Target genes of rnomiRNA-190a-5p were predicted using target gene prediction software miRBase (http://www.mirbase.org) and TargetScan (http://www.targetscan.org/vert_71/). Plasmids containing wild-type PHLPP1 Luciferase reporter gene vector (PHLPP1) and mutant PHLPP1 Luciferase reporter gene vector (PHLPP1-mut) were constructed. They were co-transfected with rno-miR-190a-5p mimics or negative control (NC), respectively into 293T cells. Luciferase activity was detected by the Dual-Luciferase Reporter Assay System (Promega, Madison, WI) after 24 h.

2.6 Western blot analysis

Three frozen rat ovaries tissues in each group were homogenized in RIPA buffer with 1% Phenylmethylsulfonyl fluoride (PMSF). Then the homogenates were centrifuged at 12,000× g for 10 min, and the supernatants were collected for western blotting. 12 µg of total protein samples were separated on SDS-PAGE gels, transferred to PVDF membranes (0.45 µm, Millipore, IPVH00010), and blocked with 5% non-fat milk in TBS containing 0.1% Tween 20 (TBST). The membranes were incubated with the following primary antibodies: anti-PHLPP1, anti-AKT, anti-p-AKT, anti-FOXO3a, anti-p-FOXO3a, anti-LHR and anti-GAPDH (1:1000, Abcam, United Kingdom), diluted in TBST-5% milk at 4°C overnight. The appropriate horseradish peroxidase-conjugated secondary antibodies were diluted 1:1000 in TBST-5% milk and incubated for 1 h at room temperature, and the protein bands were visualized with enhanced chemiluminescence (ECL).



2.7 Statistical analysis

All results are represented as a mean \pm standard error of the mean. Statistical analysis of these results was carried out by *t*-test or one-way ANOVA (with LSD or Dunnett's T3 correction for comparison of multiple means). *p* values <0.05 were considered statistically significant. All statistical analyses were done using IBM SPSS 19.0 Software.

3 Results

3.1 Identification of miRNAs that are differentially expressed earlier in when VCD treatment process

We first observed the changes of E2, FSH, LH, and AMH hormone levels in rat serum by ELISA to determine the development of POF in rats and whether it was successfully created or not. We found that with the increase of VCD-treated days (D1-D15), the LH levels increased significantly increasing the number of VCD-treatment days starting from the D6 VCDtreated group (*p* < 0.05, *p* < 0.01, *p* < 0.001, Figure 2A), the FSH level increased significantly in D15 VCD-treated group (p < 0.01, Figure 2B), the AMH level decreased significantly in D15 VCDtreated group (p < 0.001, Figure 2C) and there were no significant changes in E₂ level (Figure 2D). On the 45th day (D45), which is the day to judge whether the POF animal model is successful or not, we found that the levels of LH and FSH level were significantly increased (p < 0.001, Figures 2A,B) and the levels of E2 and AMH level in the VCD-treated groups were significantly decreased (p < 0.001, Figures 2C,D).

Then we used qRT-PCR analysis in rat ovarian tissue to observe the 6 significantly differentially expressed miRNAs (miRNA-190a-5p, miRNA-27b-3p, miRNA-29a-3p, miRNA-98-5p, miRNA-151-5p, and miRNA-144-5p), which were being screened in the POF model rat ovary by our previous research, expression level changes during VCD-treated process (D1-D15). In this study, we found that miRNA-190a-5p was significantly differentially up-regulated at the earliest in the D6 VCD-treated group, with the increase of VCD-treated days, the up-regulation trend of differential expression became more and more significantly (p < 0.001, Figure 3A) compared with other miRNAs, the expression of miRNA-144-5p was upregulated on the D15 VCD-treated group (p < 0.05, Figure 3B), and there was no significant difference in other miRNAs (Figures 3C-F). Meanwhile, this study also verified our previous findings. In the D45 VCD-treated group, miRNA-190a-5p, miRNA-27b-3p, miRNA-98-5p and miRNA-151-5p were significantly upregulated (p < 0.001, Figures 3A,C,E,F), while miRNA-144-5p and miRNA-29a-3p were significantly down-regulated (p < 0.001, Figures 3B,D).

3.2 miRNA-190-5p directly targets PHLPP1 in the VCD-treating process

PHLPP1 was selected as a candidate miRNA-190a-5p target based on bioinformatics analysis (miRBase and TargetScan). As shown in Figure 4A, PHLPP1 was found to be a possible target gene of rno-miRNA-190a-5p. Then, the dual-luciferase reporter gene assay verified that miRNA-190a-5p impaired the luciferase activity of the wild-type PHLPP1 (PHLPP1) but not the mutant PHLPP1 3'-UTR (PHLPP1-mut) in cells (Figure 4B). The result



suggested that PHLPP1 was a target of miRNA-190a-5p. We then selected rat ovarian tissues from the VCD-treated groups on the 6th (D6), 10th (D10), 15th (D15), and 45th days (D45) to detect the expression changes of miRNA-190a-5p and PHLPP1 mRNA by qRT-PCR analysis. This data showed that with the increase of

VCD treating days, the expression of miRNA-190a-5p was significantly up-regulated (p < 0.001, Figure 4C), while the expression trend of PHLPP1 was significantly down-regulated (p < 0.001, (p < 0.001,

4D). Taken together, all results verified that PHLPP1 was a direct downstream target of miRNA-190-5p in POF.

3.3 MiRNA-190a-5p targeting PHLPP1 to promote premature ovarian failure

To study the mechanism of miRNA-190a-5p to promote POF after VCD treatment. We detected the expression level of PHLPP1 mRNA and protein and its signaling pathway mRNAs and proteins, including AKT, FOXO3a, and LHR in the VCDtreated rat ovaries tissues. As shown in Figures 5, 6, with the increase of the VCD-treated process, from the VCD-treated groups on the 6th (D6), 10th (D10), 15th (D15), and 45th days (D45), the expression of PHLPP1 mRNA and protein in each model group decreased, showing a significant downward trend (p < 0.05, p <0.001, Figure 4D and Figure 6B). And the LHR mRNA and protein expression levels decreased, showing a significant downward trend (p < 0.001, Figure 5A, Figure 6C). We also found the AKT (AKT1) mRNA expression was significantly decreased (p < 0.001, Figure 5B) and the ratio between phosphorylated and non-phosphorylated AKT protein (p-AKT/AKT) was increased, showing a significant upward trend (p < 0.01, p < 0.001), but the difference in the D6 VCD-treated group was not significant (Figure 6D). Meanwhile, FOXO3a mRNA expression was significantly decreased (p < 0.001, Figure 5C), and the ratio between phosphorylated and non-phosphorylated FOXO3a protein (p-FOXO3a/FOXO3a) was increased, showing a significant upward trend (p < 0.001, Figure 6E).

4 Discussion

Premature ovarian failure (POF) is characterized by amenorrhea, infertility, low estrogen levels, excess



gonadotropins, and a lack of mature follicles before age 40 (Okeke et al., 2013). The occurrence of POF is mainly related to the continuous reduction of follicles in the ovary and the

abnormal development of follicles. The size of the primordial follicles and the maintenance of the resting state determine the speed of ovarian aging. Once the primordial follicles are exhausted, the ovaries will be rapidly depleted after losing their function, and the body will enter a state of menopause. Studies have shown that 4-vinylcyclohexene diepoxie (VCD), a common ovarian toxic chemical, accelerates ovarian failure by specifically activating primordial follicles, and persists after drug withdrawal characteristics of toxicity. In animal experiments, the different stages of ovarian function from weakened to failure can be simulated by controlling the dosage and modeling time, so it can be widely used in the study of decreased ovarian reserve, POF, and menopause-related diseases (Hoyer et al., 2001; Frye et al., 2012; Kappeler and Hoyer, 2012). In addition, compared with other modeling methods, VCD only affects gonadal tissues such as ovaries, and hardly affects other tissues or organs (Tamura et al., 2009). And some experiments have confirmed that VCD can induce POF in experimental animal models (Hoyer et al., 2001; Wright et al., 2011). Therefore, in the early stage of our study (Kuang et al., 2014; Li et al., 2014), VCD was used to successfully induce the POF animal model.

Based on our previous study, we still used the same approach to establish the POF rat model in the present study. Even for the purpose of collecting tissues during VCD modeling (i.e., during primordial follicular hyperactivation). We tested blood samples and collected rat ovarian tissue after sacrificing rats at consecutive time points of VCD injection. Hormone level is an important and sensitive indicator of ovary function. The E₂, FSH, and LH levels are classical criteria for POF (Steiner, A. Z., 2013; Nie, X et al., 2018). Clinical studies showed that patients in the POF group were found to have significantly higher FSH and LH serum concentrations and lower E2 serum levels when compared to healthy controls (Podfigurna, A et al., 2018; Qi et al., 2022). Our hormone level results are consistent with our previous findings (Kuang et al., 2014; Li et al., 2014). However, it is worth noting that in our result, we found that LH was the hormone with early differential changes in the VCD-treated process, that is, from the 6th day of treatment. In addition, some studies have shown that the change in LH level is an important link to trigger follicle ovulation in the process of follicle development (Holesh et al., 2021). Therefore, we speculate that the abnormal change in LH level caused by VCD modeling will damage the development of follicles and ovulation function.

In this study, we additionally observed the changes in serum Anti-Mullerian hormone (AMH) levels in rats during VCDtreated days. And we found that the AMH level decreased with the increase of VCD-treated time. Previous studies have shown that chemicals can destroy growing follicles, which indirectly causes a reduction in the primordial follicular pool (Wang et al., 2019), as the destruction of growing follicles leads to a decrease in AMH, which activates the primordial follicles, and an increase in follicular granulosa cells to produce AMH to inhibit



summarized and presented as mean \pm SEM from four independent experiments. *p < 0.05, **p < 0.01 and ***p < 0.001 vs. control.

further primordial follicular activation (Durlinger et al., 1999). Thus, the activation and recruitment of primordial follicles may be accelerated in mice molded using the chemical induction method due to the sudden loss of growing follicles (Baker et al., 2011). Another study showed that when ovarian function is impaired and the number of growing follicles decreases leading to a decrease in AMH, its function of maintaining the dynamic balance between follicular atresia and follicular recruitment decreases, which induces the primordial follicles to be overactivated, and this dynamic balance, if not restored, can eventually lead to POF (Moolhuijsen and Visser, 2020). Therefore, our results speculate that the overactivation of primordial follicles becomes more pronounced as the days of VCD administration increase. Hence, it is therefore important to seek novel biomarkers of primordial follicle hyperactivation.

Based on successfully replicating the POF animal model by VCD-treated, our previous study detected the most significantly differentially expressed 6 miRNAs between POF and normal rats' ovaries tissues by using the rat genome-wide miRNA expression profile chip technology, including miRNA-190a-5p, miRNA-98-5p, miRNA-29a-3p, miRNA-144-5p, miRNA-27b-3p and miRNA-151-5p (Kuang et al., 2014). Other previous studies have shown that miRNAs are involved in the maturation of mouse oocytes and the development of follicles (Dehghan et al., 2021). Hence, our study continuously monitored the expression changes of these 6 miRNAs from the first day of VCD-treated and screened out potential biomarkers that can be used in the early stage of POF disease. In our study, we found that miRNA-190a-5p was abnormally upregulated at the early stage of VCD injection, i.e., the 6th day (D6), and showed a significant upward trend with the increase of VCD-treated days. Therefore, we speculated that miRNA-190a-5p might serve as a biomarker in the early stage of POF. Usually, we also know that miRNAs exert their functions by degrading mRNAs expression (Othman and Nagoor, 2019; Tian et al., 2019). Hence, we used the publicly available databases to seek the potential targets of miRNA-190a-5p. Previous research reported that miRNA-190a directly inhibits the PH domain leucine-rich repeat protein phosphatase (PHLPP) (Yu et al., 2014). Likewise, in this study, we firstly predicted by database and then verified that miRNA-190a-5p negatively regulates its downstream target gene PHLPP1 at the early stage of POF, i.e., from the 6th day of VCD-treated POF, by double-luciferase reporter gene assay and qRT-PCR assay in rat ovarian tissues. It is thus hypothesized that miRNA-190a-5p may play a role in promoting premature ovarian failure by targeting PHLPP1.

PHLPP1 is a tumor suppressor protein that inactivates the kinase AKT through Ser437 dephosphorylation (Gao et al., 2005). A recent study showed that trivalent arsenic (A^{3+}) induces the expression of miR-190 in human bronchial epithelial cells, which binds the 3'UTR of the PHLPP transcript, decreasing PHLPP protein levels. Subsequently, AKT activation and phosphorylation levels were increased (Beezhold et al., 2011). In addition, in chemical environment induced POF models, several studies have confirmed the presence of enhanced AKT kinase signaling pathways and lead to primordial follicular hyperactivation (Sobinoff et al.,

2011; Sobinoff et al., 2012). It has even been shown that after direct or indirect activation of AKT, phosphorylated AKT can activate phosphorylation of a series of downstream proteins (FOXO3a, BCL-2, etc.), which can promote follicular cell growth and proliferation (Makker et al., 2014). Moreover, AKT activation by upstream molecules has been reported to hyperphosphorylated FOXO3a, transport it out of the nucleus, and stimulate primordial follicle initiation (John et al., 2008). Therefore, FOXO3a can also be used as a marker to determine if the primordial follicle is activated (Yan et al., 2018). Thus, in this study, we used qRT-PCR assay and Western Blot analysis to detect the effects of VCD modeling on the expression of PHLPP1, AKT, and FOXO3a mRNA and the phosphorylation levels of AKT and FOXO3a proteins in rat ovarian tissues, and observed that as the time of VCD modeling increased, the expression levels of PHLPP1 mRNA and protein decreased along with the expression levels of AKT and FOXO3a mRNA and proteins, while the phosphorylation levels of AKT and FOXO3a proteins showed a significant increase. Therefore, we hypothesized that the abnormal expression of miRNA-190a-5p was upregulated in VCD-treated rats followed by downregulation of PHLPP1, which further activated AKT and FOXO3a proteins on AKT-FOXO3a signaling pathway, thus hyperactivation primordial follicles leading to the development of POF.

As mentioned previously in this study the latest finding was that LH was the earlier hormone to show differential changes during the VCD-treated POF rat model and was significantly differentially expressed almost the same day as miRNA-190a-5p. It has been reported that LH itself induces the expression of luteinizing hormone receptor (LHR) and that the pulsatile release of LH maintains the levels of LHR and steroid hormone synthase (Plakkot et al., 2018). However, the experimental elevation of LH levels can desensitize hormonal signaling and lead to the downregulation of LHR expression (Dufau, 1998). It has been shown that mutations in the LHR gene lead to abnormal LHR function and failure to properly receive LH and stimulate hormonal signaling to the second messenger, resulting in impaired follicular maturation in the ovary, anovulation, delayed puberty, amenorrhea, infertility, with typical POF symptoms (Dixit et al., 2010). In addition, it has been shown that AKT knockout in mice is less responsive to LH processing, leading to a reduction in the number of primordial follicles in mouse ovaries (Maidarti et al., 2020). A recent study showed that cisplatin-induced primordial follicular hyperactivation in mice led to a significant reduction in the number of LHR expressions during POF (Chang et al., 2015). In our research, we found that the gene and protein expression of LHR in rat ovarian tissues showed a decreasing trend with the increase of VCD modeling time by qRT-PCR assay and Western Blot analysis. Therefore, we speculate that one of the alternative mechanisms by which VCD-induced miRNA-190a-5 promotes POF in rats may be that VCD induces miRNA-190a-5p to downregulate PHLPP1 after upregulation of abnormal expression at an early stage, which subsequently activates AKT,

causing a decrease in AKT expression, leading directly or indirectly to an abnormal elevation of LH hormone and decrease in LHR receptor expression level, thus hyperactivation primordial follicles and ultimately leading to POF.

5 Conclusion

In this study, we found that miRNA-190a-5p may become a potential biomarker for early screening of POF, and it can continuously hyperactivation primordial follicles in rats by targeting the expression of PHLPP1 and key proteins in the AKT-FOXO3a and AKT-LH/LHR pathways.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Ethics statement

The animal study was reviewed and approved by the Animal Experimental Ethical Committee of Heilongjiang University of Chinese Medicine.

Author contributions

PG, YZ, and DH conceived and designed the study. YZ, XY, and XS wrote and edited the manuscript. DH helped with revising the manuscript. YZ, XS, CZ, MZ, and JL performed most of the experiments. YZ and XS collected and analyzed the data. PG provided financial support. JW contributed important reagents and provided technical assistance and supervised the experiment. All authors contributed to the article and approved the submitted version.

Funding

This work was supported in part by grants from the Natural Science Foundation of Heilongjiang province (No. JC2018025).

Acknowledgments

We would like to acknowledge the technical expertise of the Research and Experimental Center of the Second Affiliated Hospital of Harbin Medical University. We also thank Yuxin Liu, Shuying Yuan, Hui Wang, Jiaxin Li, Siqi Chen, Zhongmin Lv, and Bo Wang for helping us with animal experiments and for assisting us in compiling and reviewing the relevant literature.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

Adhikari, D., Risal, S., Liu, K., and Shen, Y. (2013). Pharmacological inhibition of mTORC1 prevents over-activation of the primordial follicle pool in response to elevated PI3K signaling. *PloS one* 8 (1), e53810. doi:10.1371/journal.pone.0053810

Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., Van De Sluis, B., et al. (2011). Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. *Nature* 479 (7372), 232–236. doi:10.1038/nature10600

Beezhold, K., Liu, J., Kan, H., Meighan, T., Castranova, V., Shi, X., et al. (2011). miR-190-mediated downregulation of PHLPP contributes to arsenic-induced Akt activation and carcinogenesis. *Toxicol. Sci.* 123 (2), 411–420. doi:10.1093/toxsci/kfr188

Chakravarthi, V. P., Ghosh, S., Roby, K. F., Wolfe, M. W., and Rumi, M. A. (2020). A gatekeeping role of ESR2 to maintain the primordial follicle reserve. *Endocrinology* 161 (4), bqaa037. doi:10.1210/endocr/bqaa037

Chang, E. M., Lim, E., Yoon, S., Jeong, K., Bae, S., Lee, D. R., et al. (2015). Cisplatin induces overactivation of the dormant primordial follicle through PTEN/AKT/ FOXO3a pathway which leads to loss of ovarian reserve in mice. *PLoS One* 10 (12), e0144245. doi:10.1371/journal.pone.0144245

Dehghan, Z., Mohammadi-Yeganeh, S., Rezaee, D., and Salehi, M. (2021). MicroRNA-21 is involved in oocyte maturation, blastocyst formation, and pre-implantation embryo development. *Dev. Biol.* 480, 69–77. doi:10.1016/j.ydbio.2021.08.008

Dixit, H., Rao, L., Padmalatha, V., Raseswari, T., Kapu, A. K., Panda, B., et al. (2010). Genes governing premature ovarian failure. *Reprod. Biomed. Online* 20 (6), 724–740. doi:10.1016/j.rbmo.2010.02.018

Dong, S. Q., Zhao, X. L., Sun, Y., and Zhang, J. W. (2021). Comparative efficacy and safety of complementary and alternative therapies for tubal obstructive infertility: A protocol for network meta-analysis. *Medicine* 100 (7), e24810. doi:10.1097/MD.000000000024810

Dufau, M. L. (1998). The luteinizing hormone receptor. Annu. Rev. Physiol. 60 (1), 461–496. doi:10.1146/annurev.physiol.60.1.461

Durlinger, A. L., Kramer, P., Karels, B., de Jong, F. H., Uilenbroek, J. T. J., Grootegoed, J. A., et al. (1999). Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. *Endocrinology* 140 (12), 5789–5796. doi:10. 1210/endo.140.12.7204

Fernandez, S. M., Keating, A. F., Christian, P. J., Sen, N., Hoying, J. B., Brooks, H. L., et al. (2008). Involvement of the KIT/KITL signaling pathway in 4-vinylcyclohexene diepoxide-induced ovarian follicle loss in rats. *Biol. Reprod.* 79 (2), 318–327. doi:10.1095/biolreprod.108.067744

Frye, J. B., Lukefahr, A. L., Wright, L. E., Marion, S. L., Hoyer, P. B., and Funk, J. L. (2012). Modeling perimenopause in sprague–dawley rats by chemical manipulation of the transition to ovarian failure. *Comp. Med.* 62 (3), 193–202.

Gao, T., Furnari, F., and Newton, A. C. (2005). Phlpp: A phosphatase that directly dephosphorylates akt, promotes apoptosis, and suppresses tumor growth. *Mol. Cell.* 18 (1), 13–24. doi:10.1016/j.molcel.2005.03.008

Harumi, K. U. B. O. (2009). Epidemiology of infertility and recurrent pregnancy loss in society with fewer children. JMAJ 52 (1), 23–28.

Holesh, J. E., Bass, A. N., and Lord, M. (2021). *Physiology, ovulation*. Treasure Island: Statpearls.

Hoyer, P. B., Cannady, E. A., Kroeger, N. A., and Sipes, I. G. (2001). Mechanisms of ovotoxicity induced by environmental chemicals: 4-vinylcyclohexene diepoxide as a model chemical. *Adv. Exp. Med. Biol.* 500, 73–81. doi:10.1007/978-1-4615-0667-6_8

Hu, X., Roberts, J. R., Apopa, P. L., Kan, Y. W., and Ma, Q. (2006). Accelerated ovarian failure induced by 4-vinyl cyclohexene diepoxide in Nrf2 null mice. *Mol. Cell. Biol.* 26 (3), 940–954. doi:10.1128/MCB.26.3.940-954.2006

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

John, G. B., Gallardo, T. D., Shirley, L. J., and Castrillon, D. H. (2008). Foxo3 is a PI3K-dependent molecular switch controlling the initiation of oocyte growth. *Dev. Biol.* 321 (1), 197–204. doi:10.1016/j.ydbio.2008.06.017

Kappeler, C. J., and Hoyer, P. B. (2012). 4-vinylcyclohexene diepoxide: A model chemical for ovotoxicity. *Syst. Biol. Reprod. Med.* 58 (1), 57–62. doi:10.3109/19396368.2011.648820

Kuang, H., Han, D., Xie, J., Yan, Y., Li, J., and Ge, P. (2014). Profiling of differentially expressed microRNAs in premature ovarian failure in an animal model. *Gynecol. Endocrinol.* 30 (1), 57–61. doi:10.3109/09513590.2013.850659

Lee, J. H., Lee, M., Ahn, C., Kang, H. Y., Tran, D. N., and Jeung, E. B. (2017). Parabens accelerate ovarian dysfunction in a 4-vinylcyclohexene diepoxide-induced ovarian failure model. *Int. J. Environ. Res. Public Health* 14 (2), 161. doi:10.3390/ jerph14020161

Li, J., Fan, S., Han, D., Xie, J., Kuang, H., and Ge, P. (2014). Microarray gene expression profiling and bioinformatics analysis of premature ovarian failure in a rat model. *Exp. Mol. Pathol.* 97 (3), 535–541. doi:10.1016/j.yexmp.2014.10.015

Maidarti, M., Anderson, R. A., and Telfer, E. E. (2020). Crosstalk between PTEN/ PI3K/akt signalling and DNA damage in the oocyte: Implications for primordial follicle activation, oocyte quality and ageing. *Cells* 9 (1), 200. doi:10.3390/ cells9010200

Makker, A., Goel, M. M., and Mahdi, A. A. (2014). PI3K/PTEN/Akt and TSC/ mTOR signaling pathways, ovarian dysfunction, and infertility: An update. *J. Mol. Endocrinol.* 53 (3), R103–R118. doi:10.1530/JME-14-0220

Moolhuijsen, L. M., and Visser, J. A. (2020). Anti-müllerian hormone and ovarian reserve: Update on assessing ovarian function. *J. Clin. Endocrinol. Metab.* 105 (11), dgaa513–3373. doi:10.1210/clinem/dgaa513

Nie, X., Dai, Y., Zheng, Y., Bao, D., Chen, Q., Yin, Y., et al. (2018). Establishment of a mouse model of premature ovarian failure using consecutive superovulation. *Cell. Physiol. biochem.* 51 (5), 2341–2358. doi:10.1159/000495895

Okeke, T. C., Anyaehie, U. B., and Ezenyeaku, C. C. (2013). Premature menopause. Ann. Med. Health Sci. Res. 3 (1), 90–95. doi:10.4103/2141-9248.109458

Othman, N., and Nagoor, N. H. (2019). Overexpression of miR-361-5p plays an oncogenic role in human lung adenocarcinoma through the regulation of SMAD2. *Int. J. Oncol.* 54 (1), 306–314. doi:10.3892/ijo.2018.4602

Plakkot, B., Saju, S. S., and Kanakkaparambil, R. (2018). A review article on gonadotropins and their significant contribution in ovarian follicle development. *J. Pharm. Innovation* 7 (11), 433–438.

Podfigurna, A., Stellmach, A., Szeliga, A., Czyzyk, A., and Meczekalski, B. (2018). Metabolic profile of patients with premature ovarian insufficiency. *J. Clin. Med.* 7, 374. doi:10.3390/jcm7100374

Qi, Y., Zhu, Y. M., and Li, B. (2022). Comparison of animal models for premature ovarian insufficiency induced by different doses of cyclophosphamide: A network meta-analysis. *Mapp. Intimacies*. doi:10.21203/rs.3.rs-1243777/v1

Santoro, N. (2003). Mechanisms of premature ovarian failure. Ann. Endocrinol. 64 (2), 87–92.

Shelling, A. N. (2010). Premature ovarian failure. *Reproduction* 140 (5), 633–641. doi:10.1530/REP-09-0567

Sobinoff, A. P., Mahony, M., Nixon, B., Roman, S. D., and McLaughlin, E. A. (2011). Understanding the villain: DMBA-induced preantral ovotoxicity involves selective follicular destruction and primordial follicle activation through PI3K/akt and mTOR signaling. *Toxicol. Sci.* 123 (2), 563–575. doi:10.1093/toxsci/kfr195

Sobinoff, A. P., Nixon, B., Roman, S. D., and McLaughlin, E. A. (2012). Staying alive: PI3K pathway promotes primordial follicle activation and survival in response

to 3MC-induced ovotoxicity. *Toxicol. Sci.* 128 (1), 258–271. doi:10.1093/toxsci/ kfs137

Steiner, A. Z. (2013). Biomarkers of ovarian reserve as predictors of reproductive potential. *Semin. Reprod. Med.* 31 (06), 437–442. doi:10.1055/s-0033-1356479

Tamura, T., Yokoi, R., Okuhara, Y., Harada, C., Terashima, Y., Hayashi, M., et al. (2009). Collaborative work on evaluation of ovarian toxicity 2) Two-or four-week repeated dose studies and fertility study of mifepristone in female rats. *J. Toxicol. Sci.* 34, SP31–SP42. doi:10.2131/jts.34.s31

Thoma, M., Fledderjohann, J., Cox, C., and Adageba, R. K. (2021). "Biological and social aspects of human infertility: A global perspective," in *Oxford research encyclopedia of global public Health (Faculty of Arts & Social Sciences)* (New York: Oxford University Press).

Tian, Y., Chen, Y. Y., and Han, A. L. (2019). MiR-1271 inhibits cell proliferation and metastasis by targeting LDHA in endometrial cancer. *Eur. Rev. Med. Pharmacol. Sci.* 23 (13), 5648–5656. doi:10.26355/eurrev_201907_18300

Vayena, E., Rowe, P. J., and Griffin, P. D. (2002). Current practices and controversies in assisted reproduction: Report of a meeting on medical, ethical and social aspects of assisted reproduction, held at WHO headquarters. Geneva, Switzerland: World Health Organization.

Wang, Y., Liu, M., Johnson, S. B., Yuan, G., Arriba, A. K., Zubizarreta, M. E., et al. (2019). Doxorubicin obliterates mouse ovarian reserve through both primordial follicle atresia and overactivation. *Toxicol. Appl. Pharmacol.* 381, 114714. doi:10. 1016/j.taap.2019.114714

Wright, L. E., Frye, J. B., Lukefahr, A. L., Marion, S. L., Hoyer, P. B., Besselsen, D. G., et al. (2011). 4-Vinylcyclohexene diepoxide (VCD) inhibits mammary epithelial differentiation and induces fibroadenoma formation in female Sprague Dawley rats. *Reprod. Toxicol.* 32 (1), 26–32. doi:10.1016/j.reprotox.2011.05.005

Yan, H., Zhang, J., Wen, J., Wang, Y., Niu, W., Teng, Z., et al. (2018). CDC42 controls the activation of primordial follicles by regulating PI3K signaling in mouse oocytes. *BMC Biol.* 16 (1), 73–16. doi:10.1186/s12915-018-0541-4

Yu, Y., Zhang, D., Huang, H., Li, J., Zhang, M., Wan, Y., et al. (2014). NF-κB1 p50 promotes p53 protein translation through miR-190 downregulation of PHLPP1. *Oncogene* 33 (8), 996–1005. doi:10.1038/onc.2013.8

Zhou, L., Xie, Y., Li, S., Liang, Y., Qiu, Q., Lin, H., et al. (2017). Rapamycin prevents cyclophosphamide-induced over-activation of primordial follicle pool through PI3K/Akt/mTOR signaling pathway *in vivo. J. Ovarian Res.* 10 (1), 56–11. doi:10.1186/s13048-017-0350-3